ReviewGynecologic oncology research and practice2015
Immunotherapy in endometrial cancer - an evolving therapeutic paradigm.
Review in Gynecologic oncology research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04212377 (An Exploratory Study), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Identification of Interleukin-9 Producing Immune Cells in Endometrial Carcinoma and Establishment of a Prognostic Nomogram.Frontiers in immunology · 2020Trial
- Does immunotherapy hold great promise in endometrial cancer care?Frontiers in immunology · 2026Review
- Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer.British journal of cancer · 2026Article
- Article
- PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review.Life (Basel, Switzerland) · 2023Review
- The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer.Current issues in molecular biology · 2023Review
- PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.Journal of cellular and molecular medicine · 2023Article
- Mitochondrial Dysfunction Involved in the Cytotoxicity of Tramadol in Human Endometrial Carcinoma Cells.International journal of molecular sciences · 2022Article
- Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?International journal of molecular sciences · 2022Review
- Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.OncoTargets and therapy · 2022Review
- Immunotherapy in endometrial cancer: rationale, practice and perspectives.Biomarker research · 2021Review
- Review
- Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.Virchows Archiv : an international journal of pathology · 2020Article
- The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.International journal of molecular sciences · 2020Review
- Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma.Diagnostics (Basel, Switzerland) · 2020Article
- The immune microenvironment of uterine adenosarcomas.Clinical sarcoma research · 2020Article
- Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.OncoTargets and therapy · 2020Review
- Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.International journal of molecular sciences · 2019Review
- Immune check-point in endometrial cancer.International journal of clinical oncology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease is confined to the uterus, patients with metastatic or recurrent disease exhibit limited response rates to cytotoxic chemotherapy, targeted agents, or hormonal therapy. Given the unmet clinical need in this patient population, exploration of novel therapeutic approaches is warranted, and attention is turning to immunomodulation of the tumor microenvironment. Existing evidence suggests that endometrial cancer is sufficiently immunogenic to be a reasonable candidate for active and/or passive immunotherapy. In this review, we critically examine what is known about the microenvironment in endometrial cancer and what has been learned from preliminary immunotherapy trials that enrolled endometrial cancer patients, encouraging further attempts at immunomodulation in the treatment of aggressive forms of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.